QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.

NCT Number	NCT07444086
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Primary Hypercholesterolemia or Mixed Hyperlipidemia
Enrollment	510 participants
Start Date	2026-03-05
Primary Completion	2027-10-07 (estimated)
Study Completion	2028-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-02